Johnson & Johnson (NYSE:JNJ) Price Target Cut to $292.00 by Analysts at Morgan Stanley

Johnson & Johnson (NYSE:JNJ) had its target price decreased by Morgan Stanley from $294.00 to $292.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley’s target price indicates a potential upside of 14.06% from the company’s previous close.

Other analysts have also issued reports about the stock. Royal Bank Of Canada reduced their price target on shares of Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating for the company in a research note on Wednesday. Wells Fargo & Company lowered their price objective on shares of Johnson & Johnson from $282.00 to $275.00 and set an “overweight” rating on the stock in a research report on Wednesday. UBS Group set a $270.00 target price on shares of Johnson & Johnson in a research report on Wednesday. Scotiabank reiterated an “outperform” rating and set a $305.00 target price on shares of Johnson & Johnson in a research note on Thursday, July 16th. Finally, TD Cowen boosted their target price on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $274.35.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock traded up $2.10 during trading on Thursday, hitting $256.01. 3,811,157 shares of the company’s stock traded hands, compared to its average volume of 7,979,705. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. Johnson & Johnson has a 1 year low of $184.66 and a 1 year high of $281.07. The stock has a market capitalization of $616.95 billion, a P/E ratio of 38.78, a PEG ratio of 2.54 and a beta of 0.21. The business has a 50-day simple moving average of $265.80 and a 200-day simple moving average of $249.47.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.54% and a net margin of 16.20%. The company had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. During the same period last year, the company earned $2.80 EPS. Johnson & Johnson’s revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, analysts forecast that Johnson & Johnson will post 11.10 EPS for the current year.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 23,054 shares of the stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the transaction, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,779,963.81. This trade represents a 50.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. This represents a 56.90% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 87,569 shares of company stock valued at $23,064,544 in the last ninety days. Corporate insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in JNJ. Outlook Capital Management LLC bought a new position in shares of Johnson & Johnson in the second quarter worth about $28,000. Matrix Trust Co grew its position in shares of Johnson & Johnson by 56.2% during the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after purchasing an additional 54 shares in the last quarter. Montgomery Financial Services LLC bought a new stake in Johnson & Johnson during the 2nd quarter valued at approximately $43,000. Hyposwiss Advisors SA bought a new stake in Johnson & Johnson during the 4th quarter valued at approximately $42,000. Finally, Polaris Financial Partners purchased a new position in Johnson & Johnson in the 3rd quarter worth approximately $56,000. Institutional investors own 69.55% of the company’s stock.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson exceeded third-quarter earnings expectations, reporting adjusted EPS of $2.59 versus the $2.53 consensus, while revenue rose 5.9% year over year to approximately $25.4 billion. Strong Innovative Medicine growth—particularly oncology, immunology and TREMFYA—helped offset weaker device sales. Johnson and Johnson Stock Plunges 6% As Medical Device Sales Miss Wall Street Forecasts
• Positive Sentiment: Management raised its 2026 outlook to $101.0 billion–$101.4 billion in revenue and $11.05–$11.15 in adjusted EPS, broadly in line with analyst expectations. Executives also said the company remains on track to reach $100 billion in annual revenue. JNJ Q3 Earnings Call Highlights Growth Outlook and MedTech Challenges
• Positive Sentiment: Johnson & Johnson maintained its quarterly dividend at $1.34 per share, or $5.36 annualized, supporting the stock’s defensive appeal. Johnson & Johnson Dividend Information
• Neutral Sentiment: Management is considering a mid-2027 spinoff of its DePuy Synthes hips-and-knees orthopedic business. The move could sharpen the company’s strategic focus, but execution and separation costs remain uncertainties. Johnson & Johnson leaning toward spinning out hips-and-knees business
• Neutral Sentiment: Morgan Stanley expects Johnson & Johnson’s December 8 enterprise review to provide greater clarity on the company’s portfolio and longer-term outlook. Johnson & Johnson’s Enterprise Review Expected to Sharpen Outlook
• Negative Sentiment: The main overhang remains MedTech: third-quarter device revenue missed Wall Street forecasts amid soft international demand, China pricing pressure and European budget constraints. Analysts subsequently lowered several price targets, while acquisition-related costs and expected 2027 dilution also cloud the outlook. These Analysts Cut Their Forecasts on Johnson & Johnson After Q3 Results

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.